Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)

Bañales, Jesús M.; Cardinale, Vincenzo; Carpino, Guido; Marzioni, Marco; Andersen, Jesper B.; Invernizzi, Pietro; Lind, Guro Elisabeth; Folseraas, Trine; Forbes, Stuart J.; Fouassier, Laura; Geier, Andreas; Calvisi, Diego F.; Mertens, Joachim C.; Trauner, Michael; Benedetti, Antonio; Maroni, Luca; Vaquero, Javier; Macı́as, Rocı́o I.R.; Raggi, Chiara; Perugorria, María J.; Gaudio, Eugenio; Boberg, Kirsten Muri; Marin, José J.G.; Alvaro, Domenico

doi:10.1038/nrgastro.2016.51

Cited by 1,105 publications

(1,247 citation statements)

References 309 publications

Supporting

Mentioning

1,139

Contrasting

Unclassified

Order By: Relevance

“…These effects may be of special relevance in areas of East-Asia with high HCV prevalence or countries where the diagnosis of primary tumors in livers with a cirrhotic background has been recently increasing [2].…”

Section: Additional Regulatory Factorsmentioning

confidence: 99%

“…Cholangiocarcinoma (CCA) accounts for 3% of all gastrointestinal cancers and it is the second most common primary hepatic tumor after hepatocellular carcinoma [1,2]. CCA is composed of tumor cells exhibiting a phenotype of biliary epithelial cells, as well as nontumor cells, essentially myofibroblasts [3], and characterized by an aggressive behavior with early lymphatic and metastatic spread.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Epithelial-mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks

Vaquero

Guedj

Clapéron

et al. 2017

Journal of Hepatology

Self Cite

125

122

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is an aggressive tumor with a poor prognosis due to its late clinical presentation and the lack of effective non-surgical therapies. Unfortunately, most of the patients are not eligible for curative surgery owing to the presence of metastases at the time of diagnosis. Therefore, it is important to understand the steps leading to cell dissemination in patients with CCA. To metastasize from the primary site, cancer cells must acquire migratory and invasive properties by a cell plasticity-promoting phenomenon known as epithelial-mesenchymal transition (EMT). EMT is a reversible dynamic process by which epithelial cells gradually adopt structural and functional characteristics of mesenchymal cells, and has lately become a center of attention in the field of metastatic dissemination. In the present review, we aim to provide an extensive overview of the current clinical data and the prognostic value of different EMT markers that have been analyzed in CCA. We summarize all the regulatory networks implicated in EMT from the membrane receptors to the main EMT-inducing transcription factors (SNAIL, TWIST and ZEB). Furthermore, since a tumor is a complex structure not exclusively formed by tumor cells, we also address the prominent role of the main cell types of the desmoplastic stroma that characterizes CCA in the regulation of EMT. Finally, we discuss the therapeutic considerations and difficulties faced to develop an effective anti-EMT treatment due to the redundancies and bypasses among the pathways regulating EMT. 4Key Point Box -EMT is an early event of metastasis that endows tumor cells with invasive properties enabling them to spread toward other territories.-EMT contributes to CCA progression and chemoresistance.-The three families of transcription factors that regulate epithelial and mesenchymal marker expression during EMT (SNAIL, TWIST and ZEB) contribute to CCA progression.-Cells of CCA microenvironment, and not only cancer cells, lead to the activation of EMT.

show abstract

Section: Additional Regulatory Factorsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Epithelial-mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks

Vaquero

Guedj

Clapéron

et al. 2017

Journal of Hepatology

Self Cite

125

122

View full text Add to dashboard Cite

show abstract

“…iCCAs, on the other hand, show two main histological subtypes-bile ductular type (mixed), and bile duct type (mucinous). 56 Chronic hepatitis B and hepatitis C infections are identified as a risk factors for CCA especially iCCA. 57 This type of CCA usually presents with mass-forming grown pattern (>90%) while infiltrative pattern is usually seen in pCCA and dCCA.…”

Section: Answers: B and Cmentioning

confidence: 99%

Hepatobiliary Quiz Answers – 18 (2016)

Rathi

Dhiman

2016

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

“…The incidence of CCA varies by geographic regions, ranging from 0.4-3.4 per 100,000 persons-year in North America and Europe to 1-85 per 100,000 persons-year in East Asia [1]. Although CCA is a relatively uncommon cancer, its incidence has been rising worldwide over the past decade [1].…”

Section: Introductionmentioning

confidence: 99%

Non-Alcoholic Fatty Liver Disease as a Risk Factor for Cholangiocarcinoma: A Systematic Review and Meta-Analysis

Wongjarupong¹,

Assavapongpaiboon²,

Susantitaphong³

et al. 2017

Gastroenterology

View full text Add to dashboard Cite

Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)

Cited by 1,105 publications

References 309 publications

Epithelial-mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks

Epithelial-mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks

Hepatobiliary Quiz Answers – 18 (2016)

Non-Alcoholic Fatty Liver Disease as a Risk Factor for Cholangiocarcinoma: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About